Short answer
Relay Therapeutics, Inc. (RLAY) filed an 8-K current report with the SEC on May 21, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). $296.8M estimated net proceeds strengthen Relay’s funding capacity for clinical development and operations.
Relay Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $296.8M estimated net proceeds strengthen Relay’s funding capacity for clinical development and operations
- 26,354,167 shares sold at $12.00, including the fully exercised 3,437,500-share option
- Equity issuance creates material shareholder dilution and expands shares outstanding
- Expected May 22, 2026 closing remains subject to customary conditions and market risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Relay Therapeutics, Inc. 8-K filings
Get the next RLAY 8-K as it lands
Follow RLAY for push alerts, or ask the research agent what this filing means.